Prolia for better Convenience | Osteoporosis | Amgen


2-year persistence with Prolia® every 6 months is higher than with intravenous or oral bisphosphonates and other anti-osteoporosis treatments.2-4
Patient preference percentage for Prolia as compared to other anti-osteoporosis treatments.
Data are from the Swedish Prescribed Drug Register, which included postmenopausal women aged ≥50 years initiating Prolia® between May 2010 and July 2012. One injection of Prolia® (60 mg) was defined as 6-month persistence. Women were considered persistent for another 6 months if they filled their next prescription within 6 months + 56 days and survival analysis applied to the data. The study of 2,315 women showed that 12-month persistence with Prolia® was 83% (95% CI: 81–84%), and 24-month persistence was 62% (95% CI: 60–65%). An additional literature search was conducted in PubMed (until November 2013) to identify retrospective studies of persistence with oral bisphosphonates and pooled persistence estimates were calculated using a random-effects model. Forty articles were identified that met the inclusion criteria for the metaanalysis. 12-month persistence with oral bisphosphonates ranged from 10% to 78% with a pooled estimate of 45%. At 24 months, persistence with oral bisphosphonates ranged from 16% to 46%, with a pooled estimate of 30%.4
Additionally, women with low adherence to daily or weekly oral bisphosphonates reported greater treatment satisfaction when transitioned to Prolia® versus switching to a monthly oral bisphosphonate.5
In a 2-year crossover study of postmenopausal women, 91.2% preferred Prolia® injections over alendronate tablets for the long term.1

The increased adherence associated with the long-interval dosing of Prolia® may enhance clinical benefit.6
Click here to find more about the method of administration for Prolia.®

*Persistence data are pooled estimates for oral bisphosphonates, which included alendronate, risedronate, ibandronate, and etidronate.
BP: bisphosphonate; CI: confidence interval.
  1. Freemantle N, et al. Osteoporos Int. 2012;23:317–26.
  2. Hadji P, et al. Osteoporos Int. 2016;27:2967–78.
  3. Reyes C, et al. Osteoporos Int. 2017;28:2997–3004.
  4. Karlsson L, et al. Osteoporos Int. 2015;26:2401–11.
  5. Palacios S, et al. J Clin Endocrinol Metab. 2015;100:E487–92.
  6. Lakatos P, et al. Calcif Tissue Int. 2016;98:215–25.


The information contained in this site is for healthcare professionals only

I am a patient
I am a member of the public